The trusted partner for RNA success
Eclipsebio provides cutting-edge support for making the RNA medicines of tomorrow a success today. From multimodal profiling of critical quality attributes to comprehensive analytics, we provide the solutions needed to move to the clinic with confidence.
Our other RNA solutions:
Beyond advancing RNA-based medicine development through eMERGE, we also offer integrative solutions for RNA-targeting therapeutics and RNA research.
AI Training Data (eVERSE)
To support accurate AI model training for drug discovery, we provide reproducible datasets through our eVERSE platform. Prepackaged datasets are available for download and custom data can be generated from each of our assays.
Small Oligonucleotides
With our holistic approach to small oligonucleotide design and validation, we provide RNAi and ASO developers with the data needed for clinical success. Learn how we perform multiomic profiling of targets and robustly measure off-target effects.
Target Discovery and Validation
Our integrative portfolio of assays reveals disease-specific, accessible regions of target RNAs and provides deep profiling of on-target and off-target therapeutic effects. Our highly reproducible assays can also be used train AI models for the design of the next generation of small molecule drugs.
Our capabilities
Comprehensive technologies for unmatched insights
Our portfolio of proprietary technologies and bioinformatics workflows provide actionable insights into all major dimensions of RNA and therapeutic biology.
End-Seq
Map unique regulatory regions
eRibo Pro
Measure transcription and translation
eSENSE dsRNA
Measure and reduce dsRNA contamination
eSENSE m6A
Map regions of RNA methylation
eSHAPE
Directly determine RNA structure
m6A-eCLIP
Locate specific methylated bases
miR-eCLIP
Identify miRNA binding and siRNA off-targets
RBP-eCLIP
Identify where and how proteins bind
Bioinformatics
Integrative analysis solutions
What Our Partners
and Collaborators Say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures… to help improve the design of our RNAs and rationalize our internal findings."
"Eclipsebio was the only company that could perform the robust siRNA off-target binding analysis we needed. Their experimental results provided important additional insights into our own internal findings. We look forward to continuing to work with Eclipsebio in the future."
"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."
New at Eclipsebio
Discover AI success
Artificial intelligence and machine learning are revolutionizing drug discovery. eVERSE is our portfolio of next-generation sequencing data, tailored for AI model training. Discover how eVERSE provides the data needed for success here.
Explore our newest technology
A major challenge with RNA vaccines and therapies is the generation of double-stranded RNA (dsRNA) by-products. With our eSENSE dsRNA assay you can measure the level of dsRNA contaminants and determine the sequences and structures that drive dsRNA generation.
Learn with our newest blog
Precision oncology uses information on the patient's own tumor to create personalized therapies, such as RNA cancer vaccines. These therapies train a patient's own immune system to attack cancer.